Top Houston, TX Pharmaceutical Companies (29)
Don't see your company?
Create a company profile
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets.
1molar inc. is a biomedical technology company.
Pulmotect develops products that boost the innate immune system to protect against a wide range of lung infections.
ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients.
Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system.
PCCA is a complete resource for compounding pharmacies. Our members are nearly 4,000 community pharmacists in the United States, Canada, Australia and other countries around the world. We were incorporated in 1981 by a network of pharmacists who recognized the need to help patients requiring customized medications.
Anton Paar develops, produces, distributes and provides support for analytical instruments used in research, development and quality control worldwide. Ever since Mr. Anton Paar founded his one-man workshop in 1922, the Austrian based company has continuously found new ways to merge high-precision engineering with scientific curiosity. The company currently has more than 3500 employees and is active in over 170 countries worldwide. Anton Paar is the world market leader in the field of density measurement, the determination of dissolved CO2 and the analysis of materials’ deformation and flow behavior. Customers of Anton Paar include the largest international soft drink producers and breweries, petroleum and food companies, the chemical and pharmaceutical industries, Formula 1 racing teams and many more. Our innovation builds on research and development, but goes beyond technology and involves all of Anton Paar’s employees. Innovation is the art of finding answers before the question is asked. Customers deserve reliable application solutions which are precise, economic and easy to use. Anton Paar customers can always expect more.
CNS Pharmaceutical is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.
QuVa Pharma is a leader in 503B outsourced compounding, serving all 50 states with a full portfolio of sterile, ready-to-administer injectable products. QuVa was purpose-built to change the 503B industry for the better and is leading the way in making it more safe, efficient, and reliable. With unmatched expertise in cGMPs and sterile pharmaceutical manufacturing, we achieve higher than required quality and safety standards and maintain a leading FDA compliance record, so hospitals can more confidently and reliably focus on patient care. While our leading cGMP processes, sterile-to-sterile portfolio, and expansive capacity of 300,000 sq ft across four facilities are the foundation of success, it is our transparency, customer-focused service, and contracted supply arrangements that enable us to help hospitals and health systems better meet their patient care and operational needs. As FDA compliance becomes more stringent, QuVa's ability to reliably supply the highest-quality products is more valuable than ever and allows hospitals to spend more time on patient care and less time worried about beyond use dates, waste, workload inefficiencies, and compliance. That is why QuVa is proud to be recognized as the partner of choice for many of the nation’s leading health systems. So, whether you are calling for a response or being called on for a solution, know that QuVa is accountable, and in us, you always have an answer.
Animal Life Sciences focuses on the development and commercialization of treatments for cats and dogs based on human cancer technologies.
Clinical stage pharmaceutical company developing topical, non-narcotic medications to treat pain.
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ product portfolio includes seclidemstat, a reversible LSD1 inhibitor, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule targeted protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers, initiated by MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.
Nano3D Biosciences develops products for in vitro cell culturing applications.
Award-winning clinical research organization (CRO) that delivers high-quality clinical trials through strong relationships with specialization in oncology, neurology and rare diseases.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics.
Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.
Tvardi is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers.
Memgen is developing viral immunotherapies to harness the power of the immune system to cure cancer and protect people from COVID-19
Work Your Passion. Live Your Purpose.
